Profiling Auspicious Butyrylcholinesterase Inhibitory Activity of Two Herbal Molecules: Hyperforin and Hyuganin C
Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl‐ and butyrylcholinesterase. In this study, two natural m...
Saved in:
| Published in | Chemistry & biodiversity Vol. 16; no. 5; pp. e1900017 - n/a |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Wiley Subscription Services, Inc
01.05.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl‐ and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC50=141.60±3.39 μm) and hyuganin C (IC50=38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC50=46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy. |
|---|---|
| AbstractList | Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl- and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC
=141.60±3.39 μm) and hyuganin C (IC
=38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC
=46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy. Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl- and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC50 =141.60±3.39 μm) and hyuganin C (IC50 =38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC50 =46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy.Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl- and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC50 =141.60±3.39 μm) and hyuganin C (IC50 =38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC50 =46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy. Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl‐ and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC50=141.60±3.39 μm) and hyuganin C (IC50=38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC50=46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy. Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl‐ and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC 50 =141.60±3.39 μ m ) and hyuganin C (IC 50 =38.86±1.69 μ m ) were found to be the highly active inhibitors of BChE as compared to galantamine (IC 50 =46.58±0.91 μ m ) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained , particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy. |
| Author | den Haan, Helena Pérez‐Sánchez, Horacio Cerón‐Carrasco, José P. Senol Deniz, F. Sezer Orhan, Ilkay Erdogan Peña‐García, Jorge Skalicka‐Wozniak, Krystyna Trædal‐Henden, Steinar Emerce, Esra |
| Author_xml | – sequence: 1 givenname: Ilkay Erdogan surname: Orhan fullname: Orhan, Ilkay Erdogan organization: Gazi University – sequence: 2 givenname: F. Sezer surname: Senol Deniz fullname: Senol Deniz, F. Sezer organization: Gazi University – sequence: 3 givenname: Steinar surname: Trædal‐Henden fullname: Trædal‐Henden, Steinar organization: Arctic University of Norway – sequence: 4 givenname: José P. surname: Cerón‐Carrasco fullname: Cerón‐Carrasco, José P. organization: Universidad Católica San Antonio de Murcia (UCAM) – sequence: 5 givenname: Helena surname: den Haan fullname: den Haan, Helena organization: Universidad Católica San Antonio de Murcia (UCAM) – sequence: 6 givenname: Jorge surname: Peña‐García fullname: Peña‐García, Jorge organization: Universidad Católica San Antonio de Murcia (UCAM) – sequence: 7 givenname: Horacio surname: Pérez‐Sánchez fullname: Pérez‐Sánchez, Horacio email: hperez@ucam.edu organization: Universidad Católica San Antonio de Murcia (UCAM) – sequence: 8 givenname: Esra surname: Emerce fullname: Emerce, Esra organization: Gazi University – sequence: 9 givenname: Krystyna orcidid: 0000-0002-9313-5929 surname: Skalicka‐Wozniak fullname: Skalicka‐Wozniak, Krystyna email: kskalicka@pharmacognosy.org organization: Medical University of Lublin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30891904$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1v3CAQhlGVqvnqtccKqZdedjtgjO3eNtuPjZSqOSS5IswOCRELG7AT-d-XaJNUilT1BAPPM2J4D8leiAEJ-cBgzgD4F9Ov7-ccWAcArHlDDphkfMbaFvZe9g3fJ4c53xa-nLfvyH4FbVcUcUDuzlO0zrtwTRdj3jrj4pjpyThMafLmJpYbzAMmnZGehhvXuyGmiS7M4O7dMNFo6cVDpCtMvfb0V_RoRo_5K11NW0w2JheoDutSjtc6lGJ5TN5a7TO-f1qPyOWP7xfL1ezs98_T5eJsZqqmamaiRtl2VtdGMg22Z5XlUmJjQRsUogUNjWYGalOzRlqLXd3quhNgOlEbhtUR-bzru03xbixDqI3LBr3XAcuMirMCtrLpqoJ-eoXexjGF8jrFOZdCgOSiUB-fqLHf4Fptk9voNKnnzyyA2AEmxZwTWmXcoAcXw5C084qBesxMPWamXjIr2vyV9tz5n0K3Ex6cx-k_tFqefLv66_4Bh4qp6Q |
| CitedBy_id | crossref_primary_10_1002_cbdv_202200315 crossref_primary_10_1038_s41598_020_78782_5 crossref_primary_10_3390_cells12111540 crossref_primary_10_3390_molecules25173896 crossref_primary_10_1016_j_coph_2021_08_017 crossref_primary_10_3390_ijms21124475 crossref_primary_10_3390_molecules29163893 crossref_primary_10_1016_j_phytochem_2022_113526 |
| Cites_doi | 10.2174/092986710790226156 10.1097/WAD.0000000000000284 10.1254/jphs.FP0060378 10.1016/j.fct.2017.03.016 10.1016/j.cbi.2016.05.001 10.1002/jcc.540110404 10.1002/jcc.21256 10.2174/092986712800229032 10.3390/molecules181011733 10.1016/j.fct.2016.12.013 10.1007/s10072-016-2625-7 10.2478/v10007-010-0006-y 10.1016/j.neuron.2014.08.005 10.5505/tjps.2015.47965 10.1016/j.apjtm.2016.01.014 10.1016/j.ejmech.2014.05.056 10.2174/138955711796575434 10.1111/ggi.13632 10.1177/0891988718824036 10.1002/jcc.540050204 10.2174/1573407210666141001000556 10.1016/j.phrs.2015.11.023 10.1038/jcbfm.2012.164 10.1002/ana.410340312 10.17660/ActaHortic.2008.765.6 10.1016/j.bmc.2005.08.038 10.1016/j.bmc.2010.09.044 10.1023/A:1022869222652 10.1155/2014/903529 10.1016/j.phytol.2011.08.016 10.1002/jcc.21334 10.1016/0006-2952(61)90145-9 10.1103/PhysRevB.37.785 10.1002/ptr.2578 10.1055/s-0042-108738 10.1016/j.arcmed.2012.11.003 10.1016/j.neures.2014.05.006 10.1016/j.indcrop.2012.07.017 10.1016/j.cplett.2012.11.075 10.1063/1.464913 |
| ContentType | Journal Article |
| Copyright | 2019 Wiley‐VHCA AG, Zurich, Switzerland 2019 Wiley-VHCA AG, Zurich, Switzerland. |
| Copyright_xml | – notice: 2019 Wiley‐VHCA AG, Zurich, Switzerland – notice: 2019 Wiley-VHCA AG, Zurich, Switzerland. |
| DBID | AAYXX CITATION NPM 7QO 7TM 8FD FR3 K9. M7N P64 7X8 |
| DOI | 10.1002/cbdv.201900017 |
| DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Biotechnology Research Abstracts Technology Research Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Biotechnology Research Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1612-1880 |
| EndPage | n/a |
| ExternalDocumentID | 30891904 10_1002_cbdv_201900017 CBDV201900017 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Spanish Ministry of Economy and Competitiveness funderid: CTQ2017-87974 – fundername: POLTUR/PLANT-ALZH/5/2015 (Poland) – fundername: Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia funderid: 20524/PDC/18; 20988/PI/18 – fundername: Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia grantid: 20524/PDC/18 – fundername: Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia grantid: 20988/PI/18 – fundername: Spanish Ministry of Economy and Competitiveness grantid: CTQ2017-87974 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OC 29B 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACIWK ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ O66 O9- OIG P2P P2W P2X P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 UB1 V2E W8V W99 WBFHL WBKPD WIH WIK WJL WOHZO WQJ WRC WXSBR WYISQ XG1 XV2 ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION NPM 7QO 7TM 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 K9. M7N P64 7X8 |
| ID | FETCH-LOGICAL-c3737-45e689fa5c61a0fb13f266e7f0ace4480a07a1c05c5176ffe958a5940c945c1e3 |
| IEDL.DBID | DR2 |
| ISSN | 1612-1872 1612-1880 |
| IngestDate | Thu Jul 10 17:48:36 EDT 2025 Fri Jul 25 10:41:48 EDT 2025 Wed Feb 19 02:35:42 EST 2025 Tue Jul 01 00:43:44 EDT 2025 Thu Apr 24 23:11:57 EDT 2025 Wed Jan 22 16:41:28 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | natural products butyrylcholinesterase molecular docking enzyme inhibition coumarin |
| Language | English |
| License | 2019 Wiley-VHCA AG, Zurich, Switzerland. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3737-45e689fa5c61a0fb13f266e7f0ace4480a07a1c05c5176ffe958a5940c945c1e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9313-5929 |
| PMID | 30891904 |
| PQID | 2226440624 |
| PQPubID | 986337 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2194586793 proquest_journals_2226440624 pubmed_primary_30891904 crossref_citationtrail_10_1002_cbdv_201900017 crossref_primary_10_1002_cbdv_201900017 wiley_primary_10_1002_cbdv_201900017_CBDV201900017 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2019 2019-05-00 2019-May 20190501 |
| PublicationDateYYYYMMDD | 2019-05-01 |
| PublicationDate_xml | – month: 05 year: 2019 text: May 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Weinheim |
| PublicationTitle | Chemistry & biodiversity |
| PublicationTitleAlternate | Chem Biodivers |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_1_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 |
| References_xml | – ident: e_1_2_7_21_1 doi: 10.2174/092986710790226156 – ident: e_1_2_7_25_1 doi: 10.1097/WAD.0000000000000284 – ident: e_1_2_7_22_1 doi: 10.1254/jphs.FP0060378 – ident: e_1_2_7_11_1 doi: 10.1016/j.fct.2017.03.016 – ident: e_1_2_7_16_1 doi: 10.1016/j.cbi.2016.05.001 – ident: e_1_2_7_39_1 doi: 10.1002/jcc.540110404 – ident: e_1_2_7_41_1 doi: 10.1002/jcc.21256 – ident: e_1_2_7_7_1 doi: 10.2174/092986712800229032 – ident: e_1_2_7_40_1 – ident: e_1_2_7_14_1 doi: 10.3390/molecules181011733 – ident: e_1_2_7_34_1 doi: 10.1016/j.fct.2016.12.013 – ident: e_1_2_7_2_1 doi: 10.1007/s10072-016-2625-7 – ident: e_1_2_7_18_1 doi: 10.2478/v10007-010-0006-y – ident: e_1_2_7_3_1 doi: 10.1016/j.neuron.2014.08.005 – ident: e_1_2_7_15_1 doi: 10.5505/tjps.2015.47965 – ident: e_1_2_7_33_1 – ident: e_1_2_7_10_1 doi: 10.1016/j.apjtm.2016.01.014 – ident: e_1_2_7_27_1 doi: 10.1016/j.ejmech.2014.05.056 – ident: e_1_2_7_4_1 doi: 10.2174/138955711796575434 – ident: e_1_2_7_23_1 doi: 10.1111/ggi.13632 – ident: e_1_2_7_24_1 doi: 10.1177/0891988718824036 – ident: e_1_2_7_38_1 doi: 10.1002/jcc.540050204 – ident: e_1_2_7_28_1 doi: 10.2174/1573407210666141001000556 – ident: e_1_2_7_17_1 doi: 10.1016/j.phrs.2015.11.023 – ident: e_1_2_7_20_1 doi: 10.1038/jcbfm.2012.164 – ident: e_1_2_7_5_1 doi: 10.1002/ana.410340312 – ident: e_1_2_7_31_1 doi: 10.17660/ActaHortic.2008.765.6 – ident: e_1_2_7_32_1 doi: 10.1016/j.bmc.2005.08.038 – ident: e_1_2_7_30_1 doi: 10.1016/j.bmc.2010.09.044 – ident: e_1_2_7_6_1 doi: 10.1023/A:1022869222652 – ident: e_1_2_7_9_1 doi: 10.1155/2014/903529 – ident: e_1_2_7_29_1 doi: 10.1016/j.phytol.2011.08.016 – ident: e_1_2_7_43_1 – ident: e_1_2_7_42_1 doi: 10.1002/jcc.21334 – ident: e_1_2_7_35_1 doi: 10.1016/0006-2952(61)90145-9 – ident: e_1_2_7_36_1 doi: 10.1103/PhysRevB.37.785 – ident: e_1_2_7_8_1 doi: 10.1002/ptr.2578 – ident: e_1_2_7_12_1 doi: 10.1055/s-0042-108738 – ident: e_1_2_7_1_1 doi: 10.1016/j.arcmed.2012.11.003 – ident: e_1_2_7_19_1 doi: 10.1016/j.neures.2014.05.006 – ident: e_1_2_7_13_1 doi: 10.1016/j.indcrop.2012.07.017 – ident: e_1_2_7_26_1 doi: 10.1016/j.cplett.2012.11.075 – ident: e_1_2_7_37_1 doi: 10.1063/1.464913 |
| SSID | ssj0028808 |
| Score | 2.2306397 |
| Snippet | Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e1900017 |
| SubjectTerms | Alzheimer's disease butyrylcholinesterase Catalysis Cholinergics Cholinesterase coumarin Drug development enzyme inhibition Galantamine Hepatotoxicity Hydrophobicity Inhibitors Molecular docking natural products Neurodegenerative diseases Residues Therapy |
| Title | Profiling Auspicious Butyrylcholinesterase Inhibitory Activity of Two Herbal Molecules: Hyperforin and Hyuganin C |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbdv.201900017 https://www.ncbi.nlm.nih.gov/pubmed/30891904 https://www.proquest.com/docview/2226440624 https://www.proquest.com/docview/2194586793 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBYhEOilTfrcPIoChZ6cyLLlR2-bbcMmkFJKUnIz0kiiS4M3idcJ21-fGWvX7baUQnuzsGTLGs3LmvmGsTcKCku46ZG1xkdpAYBy0MVRYVAbOUrtTCkb-exjNr5ITy_V5U9Z_AEfov_hRpzRyWticG2awx-goWDsHYVmlR3mCwphCtgiq-hzjx8lcXN2uXCoxqO4yOUStVHIw9Xhq1rpN1Nz1XLtVM_xE6aXkw4RJ98O2pk5gO-_4Dn-z1dtsscLu5QPw0baYmuufso2QqXK-TN286mr7Y16jg_b5noCFDrLj9rZ_HZ-RRKUoucpmblx_KT-OjETOrznQwjFKfjU8_P7KR8jEfEtZ6Emr2ve8TH6wRRgP6m5ri02W8oNrfnoObs4_nA-GkeLag0RJHlC4OkuK0qvFWSxFt7EiUfl73IvNDh0AoUWuY5BKFBxnnnvSlVoVaYCylRB7JIXbL2e1u4V416LrLB5VnoPqQT0Cq0E42JrHDrRNh-waEmtChZQ5lRR46oKIMyyomWs-mUcsLd9_-sA4vHHnrtL4lcLZm4qScnGaPjIdMD2-9vIhnS2omuHC16h4E8VgRcmA_YybJr-VYkoSnw-jpYd6f8yh2p09P5L39r-l0E77BFdh8DMXbY-u23dHhpPM_O6Y5AHEQ4RPw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgCLEXxudWNsBISDxlc5w4H7x1HVMG64RQh3iz_CmqTelYG1D567mLm6CCEBI8OrFjx-fz3dl3vyPkpTCFRdz0yFrto7QwBvZBF0eFBmnkMLQzxWjk8VlWnadvP4nOmxBjYQI-RH_ghpzR7tfI4HggffATNdRo-xV9s8oW9OUmuYVpvRE-_-hDjyDFYXm20XAgyKO4yHmH28j4wXr7dbn0m7K5rru2wud4i-hu2MHn5GK_Weh98_0XRMf_-q975O5KNaXDsJbukxuufkBuh2SVy4fky_s2vTeIOjps5ldTg96z9LBZLK-Xl7iJogM9xjPPHT2pP0_1FO_v6dCE_BR05unk24xWQEfoZRzS8rr5a1qBKYw-9tOaqtpCscHw0JqOHpHz4zeTURWtEjZEJskTxE93WVF6JUwWK-Z1nHiQ_y73TBkHdiBTLFexYcKIOM-8d6UolChTZspUmNglj8lGPavdDqFesayweVZ6b1JuwDC03GgXW-3Ajrb5gEQduaRZoZljUo1LGXCYucRplP00Dsirvv5VwPH4Y829jvpyxc9zyTHeGHQfng7Ii_41cCJer6jawYRL2PtTgfiFyYBsh1XTd5WwooTvQ2ve0v4vY5Cjw6OPfenJvzR6Tu5Uk_GpPD05e7dLNvF58NPcIxuL68Y9BV1qoZ-13PIDIOkVWw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgCMQL37DCACMh8ZTNcex88Na1VB2waUIb2pvlT1FtSsvagMpfz13cBgpCSPDoxE4cn-8rvvsdIS-lLR3ipifOmZCI0lqQgz5NSgPayGNqp8Bs5MOjfHwq3p7Js5-y-CM-RPfDDTmjldfI4DMX9n6AhlrjvmBoVtVivlwl10TOKizeMPzQAUhx2J1tMhzo8SQtC76GbWR8b3P8plr6zdbcNF1b3TO6TfR61jHk5Hy3WZhd--0XQMf_-aw75NbKMKX9uJPukiu-vkeux1KVy_vk83Fb3BsUHe0389nEYuws3W8Wy8vlBYpQDJ_HbOa5pwf1p4mZ4Ok97dtYnYJOAz35OqVjoCK85TAW5fXz13QMjjBG2E9qqmsHzQaTQ2s6eEBOR29OBuNkVa4hsVmRIXq6z8sqaGnzVLNg0iyA9vdFYNp68AKZZoVOLZNWpkUegq9kqWUlmK2EtKnPHpKtelr7bUKDZnnpirwKwQpuwS103BqfOuPBi3ZFjyRraim7wjLHkhoXKqIwc4XLqLpl7JFXXf9ZRPH4Y8-dNfHVipvnimO2MVg-XPTIi-428CEerujaw4IrkPxCInph1iOP4qbpXpWxsoLnw2jekv4vc1CD_eHHrvX4XwY9JzeOhyP1_uDo3RNyEy_HIM0dsrW4bPxTMKQW5lnLK98Byz0UCg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profiling+Auspicious+Butyrylcholinesterase+Inhibitory+Activity+of+Two+Herbal+Molecules%3A+Hyperforin+and+Hyuganin+C&rft.jtitle=Chemistry+%26+biodiversity&rft.au=Ilkay+Erdogan+Orhan&rft.au=F+Sezer+Senol%E2%80%85Deniz&rft.au=Steinar+Tr%C3%A6dal%E2%80%90Henden&rft.au=Jos%C3%A9+P+Cer%C3%B3n%E2%80%90Carrasco&rft.date=2019-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1612-1872&rft.eissn=1612-1880&rft.volume=16&rft.issue=5&rft_id=info:doi/10.1002%2Fcbdv.201900017&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1612-1872&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1612-1872&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1612-1872&client=summon |